These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 31482065)

  • 1. Pathological Chemotherapy Response Score in Patients Affected by High Grade Serous Ovarian Carcinoma: The Prognostic Role of Omental and Ovarian Residual Disease.
    Santoro A; Angelico G; Piermattei A; Inzani F; Valente M; Arciuolo D; Spadola S; Mulè A; Zorzato P; Fagotti A; Scambia G; Zannoni GF
    Front Oncol; 2019; 9():778. PubMed ID: 31482065
    [No Abstract]   [Full Text] [Related]  

  • 2. External validation of chemotherapy response score system for histopathological assessment of tumor regression after neoadjuvant chemotherapy in tubo-ovarian high-grade serous carcinoma.
    Lee JY; Chung YS; Na K; Kim HM; Park CK; Nam EJ; Kim S; Kim SW; Kim YT; Kim HS
    J Gynecol Oncol; 2017 Nov; 28(6):e73. PubMed ID: 28758379
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic Role of Histological Tumor Regression in Patients Receiving Neoadjuvant Chemotherapy for High-Grade Serous Tubo-ovarian Carcinoma.
    Coghlan E; Meniawy TM; Munro A; Bulsara M; Stewart CJ; Tan A; Koay MHE; MaGee D; Codde J; Tan J; Salfinger SG; Mohan GR; Leung Y; Nichols CB; Cohen PA
    Int J Gynecol Cancer; 2017 May; 27(4):708-713. PubMed ID: 28441251
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A 3-Tier Chemotherapy Response Score for Ovarian/Fallopian Tube/Peritoneal High-grade Serous Carcinoma: Is it Clinically Relevant?
    Lawson BC; Euscher ED; Bassett RL; Liu J; Ramalingam P; Zhong Y; Fleming ND; Malpica A
    Am J Surg Pathol; 2020 Feb; 44(2):206-213. PubMed ID: 31651523
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemotherapy Response Score: Development and Validation of a System to Quantify Histopathologic Response to Neoadjuvant Chemotherapy in Tubo-Ovarian High-Grade Serous Carcinoma.
    Böhm S; Faruqi A; Said I; Lockley M; Brockbank E; Jeyarajah A; Fitzpatrick A; Ennis D; Dowe T; Santos JL; Cook LS; Tinker AV; Le ND; Gilks CB; Singh N
    J Clin Oncol; 2015 Aug; 33(22):2457-63. PubMed ID: 26124480
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic Value of Chemotherapy Response Score (CRS) Assessed on the Adnexa in Ovarian High-Grade Serous Carcinoma: A Systematic Review and Meta-Analysis.
    Santoro A; Travaglino A; Inzani F; Straccia P; Arciuolo D; Valente M; D'Alessandris N; Scaglione G; Angelico G; Piermattei A; Cianfrini F; Raffone A; Zannoni GF
    Diagnostics (Basel); 2022 Mar; 12(3):. PubMed ID: 35328186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Histopathologic response to neoadjuvant chemotherapy as a prognostic biomarker in tubo-ovarian high-grade serous carcinoma: updated Chemotherapy Response Score (CRS) results.
    Böhm S; Le N; Lockley M; Brockbank E; Faruqi A; Said I; Jeyarajah A; Wuntakal R; Gilks B; Singh N
    Int J Gynecol Cancer; 2019 Feb; 29(2):353-356. PubMed ID: 30683759
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data.
    Cohen PA; Powell A; Böhm S; Gilks CB; Stewart CJR; Meniawy TM; Bulsara M; Avril S; Brockbank EC; Bosse T; de Azevedo Focchi GR; Ganesan R; Glasspool RM; Howitt BE; Kim HS; Lee JY; Le ND; Lockley M; Manchanda R; Mandalia T; McCluggage WG; McNeish I; Midha D; Srinivasan R; Tan YY; van der Griend R; Yunokawa M; Zannoni GF; ; Singh N
    Gynecol Oncol; 2019 Aug; 154(2):441-448. PubMed ID: 31118141
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of a 'response score' after neoadjuvant chemotherapy in patients with high-grade serous ovarian carcinoma with complete clinical response.
    Zorzato PC; Zannoni GF; Tudisco R; Pasciuto T; Di Giorgio A; Franchi M; Scambia G; Fagotti A
    Int J Gynecol Cancer; 2020 Jan; 30(1):67-73. PubMed ID: 31754067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The chemotherapy response score is a useful histological predictor of prognosis in high-grade serous carcinoma.
    Singh P; Kaushal V; Rai B; Rajwanshi A; Gupta N; Dey P; Garg R; Rohilla M; Suri V; Ghoshal S; Srinivasan R
    Histopathology; 2018 Mar; 72(4):619-625. PubMed ID: 28914967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implications of histological tumor regression (Böhm's score) in patients receiving neoadjuvant chemotherapy for high grade serous tubal & ovarian carcinoma.
    Rajkumar S; Polson A; Nath R; Lane G; Sayasneh A; Jakes A; Begum S; Mehra G
    Gynecol Oncol; 2018 Nov; 151(2):264-268. PubMed ID: 30197060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of a Chemotherapy Response Score (CRS) System for Tubo-Ovarian High-Grade Serous Carcinoma (HGSC).
    Ditzel HM; Strickland KC; Meserve EE; Stover E; Konstantinopoulos PA; Matulonis UA; Muto MG; Liu JF; Feltmate C; Horowitz N; Berkowitz RS; Gupta M; Hecht JL; Lin DI; Jochumsen KM; Welch WR; Hirsch MS; Quade BJ; Lee KR; Crum CP; Mutter GL; Nucci MR; Howitt BE
    Int J Gynecol Pathol; 2019 May; 38(3):230-240. PubMed ID: 29750700
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Stage IVB endometrial cancer: does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control analysis.
    Landrum LM; Moore KN; Myers TK; Lanneau GS; McMeekin DS; Walker JL; Gold MA
    Gynecol Oncol; 2009 Feb; 112(2):337-41. PubMed ID: 19041126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy.
    Zhong Y; Liu J; Li X; Westin SN; Malpica A; Lawson BC; Lee S; Fellman BM; Coleman RL; Sood AK; Fleming ND
    Cancers (Basel); 2021 Feb; 13(4):. PubMed ID: 33572451
    [No Abstract]   [Full Text] [Related]  

  • 15. Chemotherapy-associated foam cell aggregates as a prognostic factor in patients with pelvic high-grade serous carcinoma receiving neo-adjuvant chemotherapy.
    Kojima N; Kuno I; Ushigusa T; Kato T; Yoshida H
    Virchows Arch; 2020 Sep; 477(3):429-436. PubMed ID: 32103350
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Preoperative omental metastasis-related maximum standardized fluorine-18-fluorodeoxyglucose uptake value can predict chemosensitivity and recurrence in advanced high-grade serous ovarian cancer patients.
    Sun Y; Liu S; Feng Z; Cheng J; Lu L; Wang M; Yuan H; Xu J; Zhang Y
    Nucl Med Commun; 2018 Aug; 39(8):761-767. PubMed ID: 30001265
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Response evaluation after neoadjuvant therapy: evaluation of chemotherapy response score and serological and/or radiological assessment of response in ovarian cancer patients.
    Ramspott JP; Baert T; MacKintosh ML; Traut A; Ataseven B; Bommert M; Heitz F; Plett H; Schneider S; Waltering KU; Heikaus S; Harter P; du Bois A
    Arch Gynecol Obstet; 2021 Oct; 304(4):1021-1032. PubMed ID: 33661392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemotherapy response score no longer predicts survival outcomes in high-grade serous ovarian cancer patients with
    Lee YJ; Shin YK; Kim NR; Kim SI; Lee YY; Park JY; Kim JW; Cho HW; Lee JY
    J Gynecol Oncol; 2024 Nov; 35(6):e73. PubMed ID: 38551024
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association of Somatic Mutations of ADAMTS Genes With Chemotherapy Sensitivity and Survival in High-Grade Serous Ovarian Carcinoma.
    Liu Y; Yasukawa M; Chen K; Hu L; Broaddus RR; Ding L; Mardis ER; Spellman P; Levine DA; Mills GB; Shmulevich I; Sood AK; Zhang W
    JAMA Oncol; 2015 Jul; 1(4):486-94. PubMed ID: 26181259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy response score as a prognostic tool in patients with advanced stage endometrial carcinoma treated with neoadjuvant chemotherapy.
    Jani I; Lastra RR; Brito KS; Liao C; Lazo I; Lee NK; Yamada SD; Kurnit KC
    Int J Gynecol Cancer; 2021 Jun; 31(6):852-858. PubMed ID: 33833085
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.